Synartro

Synartro is a Swedish life science company developing local injection treatments that chemically bind proven drugs to its novel technology platform for sustained efficacy without systemic side effects. The firm focuses on treating symptomatic osteoarthritis using its lead compound SYN321, which delivers diclofenac directly into joints to reduce inflammation and pain while providing lubrication.

• Products: SYN321 is an intraarticular injection designed as a potential second-line treatment for knee osteoarthritis that combines hyaluronan with diclofenac.
• Innovation: The company utilizes a patented local injection technology filed in 2015 to enable slow drug release, minimizing systemic exposure while maximizing therapeutic benefits within the joint.
• Industries: Synartro operates primarily within the pharmaceutical sector, targeting patients over forty who suffer from chronic joint disease affecting knees, hips, and hands.

The company is currently advancing its first-in-human phase 1/2a trial initiated in August 2025 to evaluate safety and tolerability before expecting conclusion results in early 2026.